Literature DB >> 2837191

Regulation of mRNA levels for cellular retinol binding protein in rat Sertoli cells by cyclic AMP and retinol.

W Eskild1, O Oyen, S Beebe, T Jahnsen, V Hansson.   

Abstract

The levels of mRNA for cellular retinol binding protein (CRBP) were studied in primary rat Sertoli cell cultures treated with cAMP analogues and retinol. In the presence of cyclic AMP analogues a dose- and time-dependent reduction (70-90%) of the levels of mRNA for CRBP was observed. Retinol concentrations above 10 nM induced a dose- and time-dependent increase (2-3 fold) in mRNA levels for CRBP. Assuming that CRBP is important for vitamin A action, our data indicate that both cAMP and retinol itself modulate the sensitivity of the Sertoli cells for retinol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837191     DOI: 10.1016/s0006-291x(88)80456-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Expression of cellular retinol- and cellular retinoic acid-binding proteins in the rat cervical epithelium is regulated by endocrine stimuli during normal squamous metaplasia.

Authors:  L Tannous-Khuri; P Hillemanns; N Rajan; T C Wright; D A Talmage
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

2.  A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter.

Authors:  W C Smith; H Nakshatri; P Leroy; J Rees; P Chambon
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

3.  Human NCU-G1 can function as a transcription factor and as a nuclear receptor co-activator.

Authors:  Knut R Steffensen; Mariam Bouzga; Frode Skjeldal; Cecilie Kasi; Almira Karahasan; Vilborg Matre; Oddmund Bakke; Sylvain Guérin; Winnie Eskild
Journal:  BMC Mol Biol       Date:  2007-11-16       Impact factor: 2.946

4.  Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer.

Authors:  Alice Arapshian; Silvina Bertran; Yuvarani S Kuppumbatti; Shigeo Nakajo; Rafael Mira-y-Lopez
Journal:  Mol Cancer       Date:  2004-04-27       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.